AQST vs CLOV: fair value comparison
Aquestive Therapeutics, Inc. and Clover Health Investments, Corp. · Updated 2026-10-19
AQST has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CLOV's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, CLOV currently ranks higher by quality score.
| AQST | CLOV | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $3.78 | $4.48 |
| 12-month range | $2.95–$7.01 | $1.70–$5.41 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #150 of 301 Healthcare | #148 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | — |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: AQST fair value analysis · CLOV fair value analysis